{"id":"rifampin-free-regimen","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Gastrointestinal disturbances"},{"rate":"5-10%","effect":"Hepatotoxicity"},{"rate":"5-10%","effect":"Neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This regimen typically includes a combination of drugs such as isoniazid, pyrazinamide, and ethambutol. The absence of rifampin allows for the treatment of patients who are resistant to rifampin or have adverse reactions to it.","oneSentence":"Rifampin-free regimen involves the use of rifampicin-free antitubercular drugs to treat tuberculosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:32.776Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of tuberculosis in patients who are resistant to rifampin or have adverse reactions to it"}]},"trialDetails":[{"nctId":"NCT06192160","phase":"PHASE2","title":"Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-03-11","conditions":"Pulmonary Tuberculosis","enrollment":315},{"nctId":"NCT07345325","phase":"PHASE3","title":"Rifampin-free Regimen Versus Rifampin-containing Regimen in the Treatment of Staphylococcal Prosthetic Valve Endocarditis","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2026-01","conditions":"Infective Endocarditis","enrollment":422},{"nctId":"NCT06585020","phase":"PHASE2","title":"Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2024-10-20","conditions":"Mycobacterium; Xenopi, Lung Diseases","enrollment":190},{"nctId":"NCT05047055","phase":"","title":"Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients","status":"UNKNOWN","sponsor":"Tuberculosis Research Centre, India","startDate":"2022-03-15","conditions":"Tuberculosis, Pulmonary","enrollment":550},{"nctId":"NCT03326050","phase":"EARLY_PHASE1","title":"Comparison Between Rifampicin and Gemifloxacin and Ciprofloxacin in Treatment of Rhinoscleroma","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-02","conditions":"Rhinoscleroma","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Rifampin-free regimen","genericName":"Rifampin-free regimen","companyName":"Nantes University Hospital","companyId":"nantes-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rifampin-free regimen involves the use of rifampicin-free antitubercular drugs to treat tuberculosis. Used for Treatment of tuberculosis in patients who are resistant to rifampin or have adverse reactions to it.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}